受强制性开放获取政策约束的文章 - Jack Khouri, MD了解详情
可在其他位置公开访问的文章：11 篇
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ...
Blood cancer journal 13 (1), 117, 2023
强制性开放获取政策： US National Institutes of Health
Cisplatin-mediated upregulation of APE2 binding to MYH9 provokes mitochondrial fragmentation and acute kidney injury
Y Hu, C Yang, T Amorim, M Maqbool, J Lin, C Li, C Fang, L Xue, A Kwart, ...
Cancer research 81 (3), 713-723, 2021
强制性开放获取政策： US National Institutes of Health, V Foundation, USA
Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory multiple …
N Gagelmann, D Dima, M Merz, H Hashmi, N Ahmed, N Tovar, ...
Journal of Clinical Oncology 42 (14), 1665-1675, 2024
强制性开放获取政策： Banking Foundation "la Caixa"
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
S Sidana, LC Peres, H Hashmi, H Hosoya, C Ferreri, J Khouri, D Dima, ...
Haematologica 109 (3), 777, 2023
强制性开放获取政策： US National Institutes of Health
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma
B Paul, M Liedtke, J Khouri, R Rifkin, MD Gandhi, A Kin, MY Levy, ...
Future Oncology 19 (1), 7-17, 2023
强制性开放获取政策： US National Institutes of Health
Daratumumab-based regimen in treating clonal plasma cell neoplasms in solid organ transplant recipients
CP Chaulagain, JM Diacovo, L Elson, RL Comenzo, C Samaras, F Anwer, ...
Clinical Lymphoma Myeloma and Leukemia 20 (3), e137-e143, 2020
强制性开放获取政策： US National Institutes of Health
Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia
V Adema, J Khouri, Y Ni, HJ Rogers, CM Kerr, H Awada, Y Nagata, ...
Leukemia & lymphoma 62 (3), 735-738, 2021
强制性开放获取政策： US National Institutes of Health
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
LC Peres, LB Oswald, CM Dillard, G De Avila, T Nishihori, BJ Blue, ...
Blood Advances 8 (1), 251-259, 2024
强制性开放获取政策： US National Institutes of Health
External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs
D Dima, A Li, LM Granat, P Dhillon, F Chamseddine, A Yalamanchali, ...
British Journal of Haematology 201 (2), 280-284, 2023
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
A Kansagra, A Dispenzieri, R Fraser, N Estrada-Merly, S Sidana, ...
Blood Advances 6 (13), 3991-3995, 2022
强制性开放获取政策： US Department of Defense, US National Institutes of Health
On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone
A Hubben, D Dima, T Atieh, C Chaulagain, B Faiman, C Ferraro, ...
Bone marrow transplantation 58 (5), 610-612, 2023
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定